Veranova A CDMO that manages complexity with confidence

Veranova A CDMO that manages complexity with confidence

X

Find Clinical Drug Pipeline Developments & Deals by Unicycive Therapeutics

Unicycive Therapeutics

About, Contact Details

EVENTS

Webinars & Exhibitions

Webinars & Exhibitions

PRESENTATION(s)

No Presentations

VIDEO(s)

No Video

DIGITAL CONTENT

No Content

DEVELOPMENTS

1 Drug(s) in Development

1 Drug(s) in Development

Developments

Filters

×

FILTER:

filter

Company

filter

Sponsor

filter

Country

filter

Therapeutic Area

filter

Study Phase

Active Filter(s):

Filters

Reset Filter

All Developments

Companies By Therapeutic Area

Development Status

Unicycive Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb

Details:

Renazorb (Lanthanum Dioxycarbonate) is an investigational next-generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology. it is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease.

Lead Product(s): Lanthanum Carbonate

Therapeutic Area: Nephrology Product Name: Renazorb

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 28, 2022

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY